#Taiwan #Taipei #ADC technology #Mycenax #Rin

Mycenax and RIN Join Forces to Innovate ADC Technologies

In a strategic move to further the development of advanced antibody-drug conjugates (ADCs), Mycenax Biotech Inc., a prominent contract development and manufacturing organization (CDMO) from Taiwan, has entered into a licensing agreement with Japan’s RIN Institute Inc. This partnership, announced on October 31, 2025, grants Mycenax the rights to utilize RIN's proprietary Val-Leu-Lys (VLK) linker technology across its global CDMO services.

The VLK linker technology, a breakthrough in ADC development, is recognized for its superior anti-tumor efficacy and high serum stability. This functionality paves the way for the formulation of advanced ADCs by enhancing cytotoxicity through two primary mechanisms: targeting the tumor microenvironment and improving ADC internalization.

Pei-Jiun Chen, CEO of Mycenax, expressed enthusiasm regarding the partnership, stating, "We are delighted to sign this agreement with RIN Institute, marking a significant milestone in our mission to deliver innovative and competitive ADC solutions." He further highlighted that this collaboration sharpens Mycenax's technical capabilities and underscores its commitment to developing cutting-edge ADC therapies.

This new agreement builds upon a Letter of Intent (LOI) signed earlier on April 7, 2025, which laid the groundwork for closer cooperation between Mycenax and RIN. Since its establishment in January 2016, RIN has been dedicated to the development of cancer-targeting antibodies for therapeutic and diagnostic applications, leveraging research insights from Dr. Yasuhiro Matsumura, a prominent figure in cancer therapy research.

RIN's expertise translates into efficient collaborations with the National Cancer Center (NCC), where ongoing projects revolve around ADC R&D and innovative protein-based thrombolytics. Earlier in 2023, RIN commenced Phase 1 clinical trials at NCC for its flagship anti-TMEM180 humanized antibody. This endorsement from NCC accelerates the pace of creating innovative antibodies for both cancer treatments and diagnostic purposes.

On the other side, Mycenax Biotech, established as a leading force in Taiwan’s biopharmaceutical sector, specializes in integrated biological solutions ranging from cell line development to drug manufacturing. It operates two facilities compliant with Good Manufacturing Practices (GMP) certified by major global health authorities, including EMA, PMDA, and Health Canada. In collaboration with firms such as KriSan Biotech and Spera Pharma, Mycenax is bolstering its ADC capabilities through specific conjugation expertise to meet increasing worldwide demands. Additionally, its partnerships with Alfresa Holdings, Kidswell Bio, and Chiome Bioscience aim to enhance biosimilar production within Japan, further diversifying its service offerings.

As the landscape of biopharmaceuticals continues to evolve, this partnership between Mycenax and RIN represents a significant advancement in the development of ADC technology. With the potential to revolutionize cancer treatment and therapy options, it marks a proactive step towards meeting the global healthcare challenges associated with oncology.

To stay updated with Mycenax and RIN, visit their respective websites to gain insights into their ongoing projects and future innovations in the biopharmaceutical field.